WO1994020598A1 - Eye care products containing a pheromone additive and method of using the same - Google Patents
Eye care products containing a pheromone additive and method of using the sameInfo
- Publication number
- WO1994020598A1 WO1994020598A1 PCT/US1994/002575 US9402575W WO9420598A1 WO 1994020598 A1 WO1994020598 A1 WO 1994020598A1 US 9402575 W US9402575 W US 9402575W WO 9420598 A1 WO9420598 A1 WO 9420598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- care product
- contact lens
- eye
- eye care
- pheromone
- Prior art date
Links
- 239000003016 pheromone Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims description 31
- 239000000654 additive Substances 0.000 title abstract description 8
- 230000000996 additive effect Effects 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 238000009472 formulation Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 47
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims description 36
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 34
- 229940061641 androsterone Drugs 0.000 claims description 34
- 238000004140 cleaning Methods 0.000 claims description 13
- 230000000249 desinfective effect Effects 0.000 claims description 11
- 210000000744 eyelid Anatomy 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 6
- 239000012487 rinsing solution Substances 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 229940127554 medical product Drugs 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 230000001050 lubricating effect Effects 0.000 claims 2
- 238000009736 wetting Methods 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 abstract description 9
- 210000001508 eye Anatomy 0.000 description 44
- 239000000047 product Substances 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 239000000178 monomer Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 5
- 229960002218 sodium chlorite Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- -1 phosphate ester Chemical class 0.000 description 4
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 3
- 208000010217 blepharitis Diseases 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000723 chemosensory effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000001121 vomeronasal organ Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- OUNZARDETXBPIX-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)acetic acid Chemical compound CCCCCCCCCCCCOCCOCC(O)=O OUNZARDETXBPIX-UHFFFAOYSA-N 0.000 description 1
- FPWSFGKGWVUHTF-UHFFFAOYSA-N 2-hydroxyethyl 2-methylbut-2-enoate Chemical compound CC=C(C)C(=O)OCCO FPWSFGKGWVUHTF-UHFFFAOYSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
- 239000004908 Emulsion polymer Substances 0.000 description 1
- 240000002024 Gossypium herbaceum Species 0.000 description 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000204900 Talipariti tiliaceum Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ZPRZNBBBOYYGJI-UHFFFAOYSA-L disodium;2-[1-[2-(carboxylatomethoxy)ethyl]-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCOCC([O-])=O)CC([O-])=O ZPRZNBBBOYYGJI-UHFFFAOYSA-L 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- SOGFHWHHBILCSX-UHFFFAOYSA-J prop-2-enoate silicon(4+) Chemical compound [Si+4].[O-]C(=O)C=C.[O-]C(=O)C=C.[O-]C(=O)C=C.[O-]C(=O)C=C SOGFHWHHBILCSX-UHFFFAOYSA-J 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940102544 sodium laureth-13 carboxylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/384—Animal products
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
Definitions
- the present invention generally relates to eye care products containing a pheromone additive and more particularly relates to eye care products such as contact lenses, contact lens care solutions, and eye care formulations which contain a pheromone additive which enables the user of the eye care products to feel good and to achieve a sense of comfort, well-being and satisfaction.
- Some contact lens wearers have allergic reaction to the presence of contact tenses in their eyes. As a consequence irritations in the eye or the eye lids have been observed.
- Some lid scrub solutions have been developed to alleviate such adverse allergic reactions caused by contact lenses. They can be used to wash and disinfect eye lids such that irritation or infection may be prevented.
- the present invention discloses a method of adding a pheromone additive into a variety of eye care products such as contact lenses, contact lens care solutions, and eye care solutions such as a lid scrub solution so that the contact lens wearer would experience a good feeling and sensation of comfort, well being and satisfaction when such pheromone containing eye care product is placed in the eye.
- vomeronasal organ i.e., a chemosensory organ in the nasal cavity tied to the hypothalamus
- U.S. Patent No. 4,456,587 to Keith discloses a pheromone delivery system in which emulsion polymers are used as carriers of pheromone for slow release when the aqueous mixture is sprayed onto the leaves of cotton plants for the control of cotton tree insects.
- U.S. Patent No. 4,923, 1 1 9 to Yamamoto, et al. discloses a bag-like dispenser which contains a sex pheromone compound of insects used for sustained release of the pheromone compound at a uniform emission rate over a long period of time.
- the bag-like dispenser body is formed of a specific polymeric laminated film having at least two or three layers in which one of the layers is a film of polyvinylidene chloride.
- Yamamoto, et al. compared their bag-like dispenser with other types of sustained release dispensers and claimed superiority over other types of dispensers such as microcapsuies and capillary tube-type dispensers.
- U.S. Patent No. 4,959,353 to Brown, et al. discloses a method of promotion of corneal stroma wound healing with human epidermal growth factor prepared from recombinant DNA.
- Brown, et al.'s method for treating corneal stroma wounds is to promote regeneration of the affected tissue by the incorporation of a polypeptide in ointment or cream to be used in the eye.
- Brown, et al. did not use an additive of pheromone and did not attempt to make the user of their ointment or cream to have a sense of good feeling.
- U.S. Patent No. 4,855,1 27 to Abrutyn, et al. discloses solid compositions wherein a non-cosmetic functional material is entrapped in a lattice of a crosslinked polymer during in situ polymerization of the monomers forming the polymer lattice. It provides a method for converting solid or liquid products into solid, free-flowing forms by the entrapment of the functional materials in a hydrophobic polymer lattice.
- Abrutyn, et al. do not teach the use of pheromone in a hydrophilic polymer which is the base material used in most soft contact lenses. Furthermore, Abrutyn, et al.
- the resulting polymer made by Williams contains entrapped active ingredient which tends not to exude from the polymer during storage yet is gradually released when the polymer is exposed to the atmosphere such as in the case of an air-freshener.
- the purpose of Williams' invention was to replace a portion of the hydrophilic monomer with a particular type of lipophilic polymer such that the undesirable exudation process which normally results in a greasy or wet surface can be avoided.
- U.S. Patent No. 4,310,397 to Kaetsu, et al. discloses polymer compositions containing a physiologically active substance. The polymer is polymerized by the irradiation of light or an ionizing source while maintaining the system in an anhydrous and airless condition. The Kaetsu, et al. method would not work in a soft contact lens composition made with hydrophilic polymers since the Kaetsu, et al.'s method only works in an anhydrous condition.
- an eye care solution such as a lid scrub solution containing a pheromone
- a pheromone can be used as an additional ingredient into the polymerization process of a hydrophilic contact lens such that the pheromone is incorporated in situ with the hydrophilic polymer structure.
- the pheromone is volatile in nature and can be controlled to release through a process of sustained slow release. This enables the user of the contact lens to have a comfortable and good feeling every time the lens is inserted into the eye. It is believed that the pheromone is in the water portion of the lens matrix with some pheromone bound to the matrix polymer. Pheromone slow releases by a diffusion process over a predetermined period of time depending upon how it is bound to the matrix polymer.
- the amount of the pheromone incorporated into the polymerization process is relatively small compared to the total content of the monomer. As a result, the pheromone does not interfere with the polymerization process.
- a suitable pheromones for the present invention is androsterone. However, any other pheromone capable of producing a sense of good feeling and well-being in the user may also be used.
- a pheromone is incorporated into contact lens care solutions such as those used for cleaning, disinfecting, storing, rinsing, and neutralizing.
- a small amount of pheromone is added to the solution such that every time the contact lens user uses the solution to treat the lenses and then inserts the lenses into the eyes, the user achieves a sense of comfort, good feeling, and satisfaction.
- a suitable amount of pheromone is added to the solution, it is believed that this sense of good feeling and well-being can last for extended period of time.
- a pheromone is added to an eye care solution such as a lid scrub formulation.
- an eye care solution such as a lid scrub formulation.
- the present invention is also directed to a method of using a pheromone in eye care products such as contact lenses, contact lens care solutions, and other eye care formulations.
- the method comprises the step of adding a pheromone into a polymerization process for contact lenses such that the pheromone is incorporated into the polymer in-situ or adding a pheromone to contact lens care solutions or eye care formulations by a small amount, i.e., from about 0.0001 % to about 1 5% (w/v).
- the contact lenses and the eye care formulations can then be used in the eye, or contact lenses can be treated with contact lens care solutions containing pheromone for a suitable length of time before they are inserted into the eyes.
- the present invention is directed to new and improved eye care products that incorporates a pheromone as an additive or as a base solution.
- the present invention is also directed to a method of using such eye care products.
- the pheromone specifically androsterone, acts in conjunction with the vomeronasal organ, i.e., a chemosensory organ in the nasal cavity connected to the hypothalamus, provides the user with a sense of good feeling, comfort and satisfaction when the lenses or the eye care formulations touch the eyes.
- Androsterone may exist in several chemical forms such as
- Crystals of androsterone can be obtained from acetone-ether. It has a melting point of 1 85-185.5° C. and it sublimes in high vacuum.
- a pheromone is added to the contact lens polymer by the incorporation of a pheromone in an in-situ polymerization process.
- This in-situ polymerization process can be readily employed with all kinds of materials for contact lenses such as that for conventional hard, soft, gas permeable and silicon lenses.
- it is especially suitable for soft contact lenses of hydrophilic base such as those commonly referred to as hydrogel lenses prepared by monomers such as hydroxyethyl methacrylate, hydroxyethyl methyl methacrylate, vinylpyrrolidone, glyceromethacrylate, methacrylate esters and the like.
- a suitable amount of androsterone i.e., between about 0.0001 % to about 1 5% by weight, is blended with the polymerization monomers before the monomers are poured into a mold and cured by irradiation with electron beams or radioactive rays.
- Producing the lens by polymerization and shaping is well known in the art. Any of the well known techniques may be used.
- One such method teaching the manufacture of soft contact lenses not containing androsterone is described in U.S.P.N. 4,966,924 to Hyon, et al. which is incorporated hereby by reference.
- PVA polyvinyl alcohol
- a mixture of solvents containing 20% by weight of water and 80% by weight of dimethyl sulfoxide are added so as to obtain a solution containing 10% by weight of PVA and 1 % by weight of androsterone.
- the solution is poured into a mold and allowed to stand for 1 hour in a freezer kept at -20° C.
- a pheromone is incorporated into contact lens care solutions.
- a pheromone of androsterone is added to a lens care solution for contact lens disinfection containing sodium chlorite and polyvinyl pyrrolidone (PVP).
- PVP polyvinyl pyrrolidone
- the amount of androsterone used is 0.3% and 0.6% (w/v), respectively.
- a preferred amount of pheromone to be used is between about 0.0001 % to 1 5 % (w/v).
- a more preferred amount of pheromone to be used is between about 0.01 % to 5% (w/v).
- a pheromone of androsterone is blended with contact lens disinfecting solutions containing sodium chlorite and polyvinyl pyrrolidone.
- Androsterone is blended with contact lens disinfecting solutions containing sodium chlorite and polyvinyl pyrrolidone.
- PVP is used in ophthalmic preparations in order to increase the viscosity of the solution. In some eye drops PVP is used to prolong the therapeutic action of substances such as pilocarpine and to promote the bioavailability of drugs. PVP is also used in solutions for contact lenses. Various grades of PVP are commercially available from BASF Aktiegensellschaft of Ludwigshafen, Germany under the name of Kollidon ® .
- K-1 2 PF molecular weight « 2,900
- K-1 7 PF molecular weight « 9,000
- K-30 molecular weight « 45,000
- a pheromone of androsterone is added to a lens care solution for contact lens cleaning and disinfecting containing a non-ionic surfactant and a triquaternary phosphate ester.
- the amount of androsterone used in Examples 3 and 4 was 0.8% and 1 .6% (w/v), respectively. However, it is believed that any other suitable amount in between 0.0001 % to 15% (w/v) may also be used to achieve the same desirable result.
- Example 3 A cleaning, disinfecting, and rinsing solution for contact lenses containing 30 androsterone is prepared with the following composition:
- a new and improved cleaning, disinfecting, and rinsing solution for contact lenses containing androsterone is prepared by the following composition.
- a suitable family of surfactants for use in Examples 3 and 4 can be obtained commercially from the BASF Corporation under the trade name of Pluronic ® surfactants.
- This family of block copolymers can be generally described as polyoxyethylene/polyoxypropylene condensation polymers terminated in primary hydroxyl groups.
- Phospholipid ® PTC is a microbiocidal agent of a triquatemary phosphate ester of cocoamidopropyl PG dimonium chloride phosphate. It is commercially available from Mona Industries.
- a pheromone is added to a variety of eye care products.
- An illustrative example is shown below in which androsterone is added to a lid scrub formulation.
- a suitable percentage of androsterone to be used is between about 0.0001 % to about 1 5 % (w/v).
- Example 5 and Example 6 each shows a non-irritating liquid cleansing composition for cleaning eye lids.
- Either composition can be used to alleviate or prevent the symptoms of Blepharitis, a common chronic inflammation of the eye lids characterized by a scaly crust on the lid margins. This condition is frequently caused by a bacteria infection, an allergic reaction, or associated with seborrhea of the face and scalp.
- Blepharitis a common chronic inflammation of the eye lids characterized by a scaly crust on the lid margins. This condition is frequently caused by a bacteria infection, an allergic reaction, or associated with seborrhea of the face and scalp.
- the lid scrub formulations disclosed in Examples 5 and 6 contain a major ingredient of a mixture of surfactants marketed by Miranol Chemical Company (Dayton, N.J.) under the trade name of MS-2.
- This mixture of surfactants includes PEG-80, sorbitanlaurate, sodium trideceth sulphate, PEG-1 50 distearate, cocamidopropylhydroxy sultaine, lauroamphocarboxy glycinate, and sodium laureth-13 carboxylate.
- the compositions also include sodium chloride, an emollient and surfactant agent of PEG-15 tallow polyamine, a micro biological preservative which may be Quaternium-1 5, or benzyl alcohol, and optionally, a chelating agent such as sodium EDTA.
- Quaternium-1 5 is well known for its microbiological preservative property and has been used as an ingredient in skin care compositions.
- N-(3-chloroallyl) hexamminium chloride a quaternary ammonium salt marketed by Dow Chemical Company under the trade name of Dowacil ® 200.
- the lid scrub composition not containing androsterone is disclosed in U.S.P.N. 4,904,698 which is incorporated hereby by reference.
- the applications of the lid scrub composition are greatly enhanced by the addition of a pheromone of androsterone at either 0.3% (w/v) or 0.6% (w/v).
- Eye lid cleaning is normally regarded as a tedious and unpleasant task for someone to rid of Blepharitis problem since washing the eye lids would inevitably involve touching or rubbing against the eye balls.
- the patient feels good every time the eye lids are cleaned by the novel lid scrub composition. The good feeling can last for a period of time during which the patient feels relaxed and satisfied.
- This novel invention of adding pheromone to lid scrub compositions therefore greatly ease the burden on the patient and turning an unpleasant task into a pleasant one.
- compositions disclosed in Examples 1 through 6 are merely given as illustrative examples, any suitable pheromone can be added to any other eye care product. It is worth noting that since androsterone has limited solubility in water, it may be desirable to add a suspending agent or dispersant into the aqueous solution to facilitate the dispersion of androsterone in the eye care or lens care product. Androsterone may also be ground to very small particle size to achieve better dispersion in water.
- the present invention may also include applications in nose spray or spray useful in dental applications.
- Pheromone may be added to a nose spray or a spray or solution used in dental applications to make the patient feel good.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Eyeglasses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6520297A JPH08507884A (en) | 1993-03-12 | 1994-03-10 | Eye care product containing pheromone additive and method of using the same |
EP94911527A EP0688357A1 (en) | 1993-03-12 | 1994-03-10 | Eye care products containing a pheromone additive and method of using the same |
AU64012/94A AU6401294A (en) | 1993-03-12 | 1994-03-10 | Eye care products containing a pheromone additive and method of using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3115393A | 1993-03-12 | 1993-03-12 | |
US08/031,153 | 1993-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994020598A1 true WO1994020598A1 (en) | 1994-09-15 |
Family
ID=21857904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/002575 WO1994020598A1 (en) | 1993-03-12 | 1994-03-10 | Eye care products containing a pheromone additive and method of using the same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0688357A1 (en) |
JP (1) | JPH08507884A (en) |
AU (1) | AU6401294A (en) |
CA (1) | CA2157934A1 (en) |
WO (1) | WO1994020598A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000060038A1 (en) * | 1999-04-02 | 2000-10-12 | Laboratoire Medidom S.A. | A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses |
AU726674B2 (en) * | 1998-04-20 | 2000-11-16 | Illinois Tool Works Inc. | Fastener driving tool for trim applications |
WO2008144494A1 (en) * | 2007-05-18 | 2008-11-27 | Alcon Research, Ltd. | Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions |
WO2012103186A3 (en) * | 2011-01-26 | 2012-09-20 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020823A1 (en) * | 1992-04-21 | 1993-10-28 | The Schepens Eye Research Institute, Inc. | Ocular androgen therapy in sjögren's syndrome |
-
1994
- 1994-03-10 WO PCT/US1994/002575 patent/WO1994020598A1/en not_active Application Discontinuation
- 1994-03-10 CA CA 2157934 patent/CA2157934A1/en not_active Abandoned
- 1994-03-10 JP JP6520297A patent/JPH08507884A/en active Pending
- 1994-03-10 EP EP94911527A patent/EP0688357A1/en not_active Withdrawn
- 1994-03-10 AU AU64012/94A patent/AU6401294A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020823A1 (en) * | 1992-04-21 | 1993-10-28 | The Schepens Eye Research Institute, Inc. | Ocular androgen therapy in sjögren's syndrome |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU726674B2 (en) * | 1998-04-20 | 2000-11-16 | Illinois Tool Works Inc. | Fastener driving tool for trim applications |
US6528465B1 (en) | 1999-04-02 | 2003-03-04 | Laboratoire Medidom S.A. | Viscosity enhanced ophthalmic solution, having a detergent action on contact lenses |
WO2000060038A1 (en) * | 1999-04-02 | 2000-10-12 | Laboratoire Medidom S.A. | A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses |
AU2008254858B2 (en) * | 2007-05-18 | 2013-06-20 | Alcon Research, Ltd. | Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions |
WO2008144494A1 (en) * | 2007-05-18 | 2008-11-27 | Alcon Research, Ltd. | Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions |
US9119772B2 (en) | 2011-01-26 | 2015-09-01 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
WO2012103186A3 (en) * | 2011-01-26 | 2012-09-20 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
RU2599036C2 (en) * | 2011-01-26 | 2016-10-10 | Аллерган, Инк. | Androgen composition for treating ophthalmic conditions |
US9504646B2 (en) | 2011-01-26 | 2016-11-29 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
AU2012209184B2 (en) * | 2011-01-26 | 2017-06-15 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
US9937188B2 (en) | 2011-01-26 | 2018-04-10 | Allergan, Inc. | Non-irritating testosterone emulsions |
US10780098B2 (en) | 2011-01-26 | 2020-09-22 | Allergan, Inc. | Non-irritating testosterone emulsions |
US10905696B2 (en) | 2011-01-26 | 2021-02-02 | Allergan, Inc. | Androgen composition for treating an ophthalmic condition |
Also Published As
Publication number | Publication date |
---|---|
AU6401294A (en) | 1994-09-26 |
EP0688357A1 (en) | 1995-12-27 |
JPH08507884A (en) | 1996-08-20 |
CA2157934A1 (en) | 1994-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2988658B2 (en) | Non-aqueous emollient-containing iodophor formulation | |
US5716611A (en) | Emollient antimicrobial formulations containing povidone iodine | |
JP4927240B2 (en) | Hydroalcohol composition viscosified using polymer | |
JP4183830B2 (en) | Alcohol-based antimicrobial composition having a cosmetic appearance | |
JP5318351B2 (en) | Compositions and methods for preoperative skin disinfection | |
US3687855A (en) | Solid iodophor cleansing compositions | |
US7754770B2 (en) | Antimicrobial composition | |
DE69730621T2 (en) | HYDRO-ALCOHOLIC COMPOSITIONS THAT ARE COMPRESSED BY COMPLEXES OF BORDER-ACTIVE COMPOUNDS WITH POLYMERS | |
KR101555341B1 (en) | Antibiotic wet tissue, and manufacturing method thereof | |
EP0053451B1 (en) | Contact lens disinfecting and preserving solution (polymeric) | |
JP2006505501A (en) | Ophthalmic, pharmaceutical and other health care preparations with naturally occurring plant compounds, extracts and derivatives | |
WO2000019981A1 (en) | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide | |
US20110020474A1 (en) | Methods of Treating Infections of the Nail or Skin Using Hypohalite | |
US4443429A (en) | Contact lens disinfecting and preserving solution (polymeric) | |
JP2025061046A (en) | Liquid Compositions Comprising Chitosan for Influencing the Skin Microbiota of a Subject - Patent application | |
CN112272578A (en) | Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity | |
WO1994020598A1 (en) | Eye care products containing a pheromone additive and method of using the same | |
MXPA01003507A (en) | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide. | |
JP3253769B2 (en) | Chlorhexidine-containing disinfectant composition | |
US20230381217A1 (en) | Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease | |
RU2803308C1 (en) | Method for hygienic treatment of facial prostheses | |
JP2006149553A (en) | Ophthalmic solution | |
JP2002136578A (en) | Cleaning, disinfecting and preserving methods for liquids for soft contact lenses and soft contact lenses | |
TWI243679B (en) | Compositions including antibiotics and methods for using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994911527 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2157934 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1994911527 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994911527 Country of ref document: EP |